Lose the weight. Keep your body.
● fulm is built for what rapid weight loss takes from the body, whether the cause is GLP-1 medications or any calorie restrictive diet.
Lose the weight. Keep your body.
● fulm is built for what rapid weight loss takes from the body, whether the cause is GLP-1 medications or any calorie-restrictive diet.
SIDE E
GLP-1
GLP-1 medications work the way they’re supposed to. They reduce appetite. You eat less. †
But accelerated weight loss comes at a cost. Fewer calories also mean fewer nutrients. Your body burns through fat, but it also burns through muscle. And losing weight that fast puts strain on the body. This isn’t a flaw in the medication. It’s what rapid weight loss does to the body.
22%
of GLP-1 users develop a new nutritional deficiency within a year.‡
~25%
of weight lost on GLP-1 medications is lean tissue, not fat.°
22%
of GLP-1 users develop a new nutritional deficiency within a year.‡
~25%
of weight lost on GLP-1 medications is lean tissue, not fat.°
Rapid weight loss leaves is linked
to documented changes in gallbladder function, oral health, and hair loss.^
Formulated under Open-Source Science ™ — the standard we hold every fulm product to.
We built it for the gap most supplements miss: the body eating 30 to 50% less food, losing weight quickly, and still asking its systems to function at full strength.
Every dose published. Every study cited.
The first production run is intentionally limited. Every batch is held to the same standard we publish.
Early access opens 48 hours before public launch. Sign up below for priority ordering.
The first production run is intentionally limited. Every batch is held to the same standard we publish.
Early access opens 48 hours before public launch. Sign up below for priority ordering.
When weight comes off fast, the body needs more support, not less.
We built fulm for that. Coming soon.
When weight comes off fast,
the body needs more support, not less.
the body needs more support, not less.
We built fulm for that. Coming soon.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
† Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. (Semaglutide 1.0mg ad libitum study, n=30.)
‡ Butsch WS, Sulo S, Chang AT, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists. Obesity Pillars. 2025;15:100186. (Retrospective cohort, n=461,382 U.S. adults.)
° Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition. Metabolism. 2025;164:156113. (Network meta-analysis, 22 RCTs, n=2,258.)
^ Composite reference: gallbladder — He et al., JAMA Internal Medicine, 2022 (meta-analysis, 76 RCTs); oral health — Mawardi et al., Cureus, 2023; hair retention — documented in GLP-1 prescribing information and FAERS adverse event reporting. Full citations on the /science page.
Fulm Inc. | 2026